Sign In

David Esposito

President and Chief Executive Officer at ONL Therapeutics

David Esposito is a distinguished healthcare CEO and combat veteran known for his success in building and expanding various healthcare companies, leading to profitable acquisitions. He served as the CEO of Armune BioScience, which was acquired by Exact Sciences in December 2017, and as the US President of Phadia US/AB, which was acquired by Thermo Fisher Scientific in September 2011. David holds a Bachelor of Science in Civil Engineering from the United States Military Academy at West Point and an MBA in General Management from Syracuse University's Martin J. Whitman School of Management.

Highlights

Feb 6 · linkedin

Great to be at the 2023 BIO CEO & Investor Conference in NYC this week. ONL1204 is Phase 2 ready across 3 indications. Here we go!! ONL Therapeutics

Dec 4 · linkedin

Just finished up a great OIS XII 2022 Year End Meeting in San Diego. So grateful for Ophthalmology Innovation Source team for putting on a great event. Also thankful for the hard work of the ONL team and the VC investors and investment bankers in attendance that awarded our ONL Therapeutics team the 2022 Ophthalmology Innovation Award! Thank you. InFocus Capital Partners ExSight Ventures and others in attendance. Connie Chang Andrew Kocab David Zacks Sushanta Mallick,

David Esposito
Add to my network

Location

Ann Arbor, Michigan, United States